Would you consider giving neoadjuvant therapy using a KEYNOTE-522 regimen to someone with cT1c cN0 TNBC?  

I would treat a larger cT1cN0 TNBC in a young, fit patient with neoadjuvant ddAC-T. As you point out, such a patient would not have been eligible for KEYNOTE-522 (which only enrolled stage II-III patients), and I do not think the added potential toxicity of the pembro and carbo are worth the unknown...